{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001119774","name":"COMPUGEN LTD","summary":"Compugen Ltd. is a clinical-stage therapeutic discovery and development company using Unigen, its AI/ML-powered computational discovery platform, to identify novel drug targets and develop cancer immunotherapy therapeutics. Its pipeline includes COM701 (anti-PVRIG antibody), COM902 (anti-TIGIT antibody), rilvegostomig (PD-1/TIGIT bispecific, licensed to AstraZeneca), and GS-0321/COM503 (IL-18BP blocker, licensed to Gilead), all targeting solid tumors.","people":[],"products":[{"name":"COM701","type":"platform","description":"Potential first-in-class humanized anti-PVRIG antibody for cancer immunotherapy, currently in blinded randomized ovarian cancer platform trial (MAIA-ovarian)."},{"name":"COM902","type":"platform","description":"Potential best-in-class fully human anti-TIGIT antibody with non-active Fc tail; Phase 1 completed, no new trials planned."},{"name":"Rilvegostomig","type":"platform","description":"PD-1/TIGIT bispecific antibody with TIGIT component derived from COM902, licensed to AstraZeneca, in multiple Phase 1/2/3 trials."},{"name":"GS-0321 (COM503)","type":"platform","description":"Potential first-in-class high affinity antibody blocking IL-18BP/IL-18 interaction, licensed to Gilead, in Phase 1 clinical trial."},{"name":"Unigen","type":"platform","description":"AI/ML-powered computational discovery platform used to identify novel drug targets and inform drug development."}],"partnerships":[{"partner_name":"AstraZeneca","partnership_type":"licensing","description":"Exclusive license for rilvegostomig (PD-1/TIGIT bispecific derived from COM902); AstraZeneca conducting multiple Phase 1/2/3 trials.","start_date":null},{"partner_name":"Gilead","partnership_type":"licensing","description":"GS-0321 (COM503) licensed to Gilead; Compugen conducting Phase 1 trial evaluating monotherapy and combination with zimberelimab.","start_date":null},{"partner_name":"Bristol Myers Squibb","partnership_type":"development","description":"BMS-986207 (anti-TIGIT) evaluated in combination with COM701 and nivolumab in Phase 1 clinical expansion cohorts.","start_date":null}],"affiliations":[],"origin":{"leaf":"766d5e0b9bb5bbc98062149f3eb1119b60392651c745a6471a123c6167fb6d95","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"22bec12549622459f33636593c26404d9a4e2a8f1c9dc0c64b57ca80ea987436","parent":"6e701c008afffba1ff5148e49e81f58b80e2ccfe5c192bf0bed95afa6d1566d1","source":"0001178913-26-000663","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":98,"hourly_limit":500,"remaining":402,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}